BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37537787)

  • 21. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
    Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
    Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
    Li J; Wang J; Chen R; Bai Y; Lu X
    Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-Infiltrating Lymphocytes in Biopsy Specimens Obtained 7 Days after Starting Chemoradiotherapy for Rectal Cancer Are Predictors of the Response to Chemoradiotherapy.
    Miyakita H; Sadahiro S; Suzuki T; Chan LF; Ogimi T; Okada K; Yamamoto S; Kajiwara H
    Oncology; 2020; 98(12):869-875. PubMed ID: 32799200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-Infiltrating PD-1+ Immune Cell Density is Associated with Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.
    Kitagawa Y; Akiyoshi T; Yamamoto N; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Fukunaga Y; Hirota T; Noda T; Kawachi H
    Clin Colorectal Cancer; 2022 Mar; 21(1):e1-e11. PubMed ID: 35123891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Digitally assessed lymphocyte infiltration in rectal cancer biopsies is associated with pathological response to neoadjuvant therapy.
    Jepsen DNM; Høeg H; Bzorek M; Orhan A; Eriksen JO; Gögenur I; Reiss B; Fiehn AK
    Hum Pathol; 2024 Feb; 144():61-70. PubMed ID: 38157991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Changes in the CD8+ Density of Tumor Infiltrating Lymphocytes after Neoadjuvant Radiochemotherapy in Patients with Rectal Adenocarcinom].
    Buka D; Dvořák J; Sitorová V; Hátlová J; Richter I; Sirák I
    Klin Onkol; 2016; 29(3):204-9. PubMed ID: 27296405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A type I interferon footprint in pre-operative biopsies is an independent biomarker that in combination with CD8
    Rezapour A; Rydbeck D; Byvald F; Tasselius V; Danielsson G; Angenete E; Yrlid U
    Oncoimmunology; 2023; 12(1):2209473. PubMed ID: 37180638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer.
    Baretti M; Zhu Q; Fu W; Meyer J; Wang H; Anders RA; Azad NS
    Oncotarget; 2022; 13():907-917. PubMed ID: 35937503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-Infiltrating Lymphocytes as Biomarkers of Treatment Response and Long-Term Survival in Patients with Rectal Cancer: A Systematic Review and Meta-Analysis.
    Orhan A; Khesrawi F; Tvilling Madsen M; Peuliche Vogelsang R; Dohrn N; Kanstrup Fiehn AM; Gögenur I
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
    Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
    Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
    Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
    Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune checkpoint proteins (PD-L1 and CTLA-4) in endometrial carcinoma: prognostic role and correlation with CD4
    Khalifa R; Elsese N; El-Desouky K; Shaair H; Helal D
    J Immunoassay Immunochem; 2022 Mar; 43(2):192-212. PubMed ID: 34697997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma.
    Hongo T; Kuga R; Miyazaki M; Komune N; Nakano T; Yamamoto H; Koike K; Sato K; Kogo R; Nabeshima K; Oda Y; Nakagawa T
    Laryngoscope; 2021 Dec; 131(12):2674-2683. PubMed ID: 34143491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of neoadjuvant chemoradiotherapy on infiltrating immune cells in the tumor microenvironment of rectal cancer].
    Yang Q; Zhou C; Han C; Zhang Y; Jiang Y; Li Z; Ma J
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(8):1270-1276. PubMed ID: 34549721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
    Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
    Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.